Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Cancer Lett. 2023 May 19;565:216220. doi: 10.1016/j.canlet.2023.216220

Table 1.

List of the approved anti-cancer liposomal drugs for use in humans by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Product Active Ingredient Target treatment/s Ref
DaunoXome® Daunorubicin citrate Kaposi’s sarcoma in HIVpositive patients and Acute myeloid leukemia [71]
Lipodox® Doxorubicin Breast and ovarian, multiple myeloma [72]
Doxil®/Caelyx® Doxorubicin hydrochloride Breast and ovarian, multiple myeloma and Kaposi’s sarcoma
Promitil® Mitomycin-C Solid Tumors and multi-drug resistant cancers [73]
Myocet Doxorubicin hydrochloride Breast neoplasms [74]
Onivyde Irinotecan Pancreatic neoplasms [75]
Vyxeos Cytarabine + daunorubicin Hydrochloride Acute myeloid leukemia [76]
Zolsketil Doxorubicin hydrochloride Breast and ovarian, multiple myeloma and Kaposi’s sarcoma [77]
DepoCyt Cytarabine Neoplastic meningitis [78]
Marqibo Vincristine sulfate Hematologic malignancies and solid tumors [79]
Mepact Mifamurtide Non-metastatic osteosarcoma [80]